Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tangshen prescription
- Development stage
- Unknown
- Lead developer
- Guang'anmen Hospital
- Administration
- Oral
01
Overview
Tangshen prescription is a Traditional Chinese Medicine (TCM) herbal formula developed by the Taizhou Hospital of Traditional Chinese Medicine for the treatment of diabetic kidney disease (DKD) and type 2 diabetes mellitus. The prescription is designed around the concept of "co-management of sugar, kidney, and syndrome," which seeks to integrate Western medical standards for DKD management with TCM macro syndrome differentiation. It is intended for use in non-dialysis patients to improve both clinical symptoms and biochemical markers of disease progression. The formula is currently undergoing clinical evaluation to further elucidate its therapeutic mechanisms and support its broader clinical application.
02
Targets
PXR (Pregnane X receptor)PR (Progesterone receptor)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on Tangshen prescription.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tangshen prescription.